-
Field test results of a integrated microfluidic-based diagnostic device indicate that the potential "lab-on-a-chip" might be able to perform complex laboratory assays in a simple, convenient manner.
-
The Food and Drug Administration (FDA) added a "black box" warning in 2004 to the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City; Medroxyprogesterone Acetate Injectable Suspension USP, Teva Pharmaceuticals USA, North Wales, PA) advising that prolonged use might result in bone mineral density loss.
-
Alert your patients of a counterfeit form of emergency contraception (EC), labeled as Evital. The Food and Drug Administration (FDA) has issued a warning on the drug.
-
How many times have you prescribed oral contraceptives (OCs) for a woman at one visit, only to find that she has discontinued the method by the next exam due to financial inability to cover her insurance copay on the pill pack?
-
The American College of Obstetricians and Gynecologists (ACOG) has issued new breast cancer screening guidelines that recommend mammography screening be offered annually to women beginning at age 40.
-
Results of three large studies, presented at the recent International AIDS Society (IAS) Conference on HIV Pathogenesis, indicate that pre-exposure prophylaxis of antiretrovirals can prevent HIV when used by heterosexual men and women.
-
(Editor's Note: Read the September 2011 edition of Contraceptive Technology Update for the second of our two-part special coverage of long-acting reversible contraceptives. Included in the upcoming issue is an in-depth look at the American College of Obstetricians and Gynecologists' new practice bulletin on the use of long-acting reversible contraceptives. The new recommendations offer guidance in selecting appropriate candidates for such methods and provide tips on managing clinical issues that might arise.)
-
-
Research indicates that while many young women might initiate vaccination for human papillomavirus (HPV), they do not complete the three-injection course of treatment.
-
Findings from a new analysis indicate that women pay a higher percentage out of pocket when it comes to oral contraceptive (OC) expenditures.